YOYutaka Oiso

Yutaka Oiso

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yutaka Oiso has a total of 37 co-authors. Here are the top co-authors by number of shared publications:

  • Yasumasa Iwasaki

    Department of Endocrinology, Metabolism, and Nephrology, Kochi Medical School, Kochi University, Nankoku, Japan

    6 shared publications
  • Hidehiko Saito

    First Department of Internal Medicine (M.M., E.Y., A.N., N.M., M.Y., M.A., Y.O., H.S), Nagoya University School of Medicine, Nagoya 466-8550, Japan

    3 shared publications
  • Hiroshi Arima

    Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine

    3 shared publications
  • Hisashi Yokoi

    First Department of Internal Medicine (S.K., T.M., H.A., H.Y., Y.M., Y.O.), Nagoya University School of Medicine, Showa-ku, Nagoya 466-8550, Japan

    3 shared publications
  • Kazuki Fukuoka

    Department of Endocrinology and Diabetes, Nagoya Ekisaikai Hospital, Nakagawawa-ku, Japan

    3 shared publications
  • Kunikazu Kondo

    First Department of Internal Medicine, Nagoya University School of Medicine, Nagoya 466, Japan

    3 shared publications

Latest Publications

  • Open Access

    Vasopressin, my best friend for life & Dr. Gary L. Robertson, the founder of the vasopressin world

    by Yutaka Oiso

    Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.

  • Open Access

    A novel loss-of-function mutation of GATA3 (p.R299Q) in a Japanese family with Hypoparathyroidism, Deafness, and Renal Dysplasia (HDR) syndrome

    by Tetsuji Okawa, Masanori Yoshida, Takeshi Usui, Takahiro Kudou, Yasumasa Iwasaki, Kazuki Fukuoka, Norio Takahashi, Yuka Uehara, Yutaka Oiso

    Hypoparathyroidism, deafness, and renal dysplasia (HDR) syndrome is a rare autosomal dominant disorder caused by mutations in the zinc finger transcription factor gene, GATA3. GATA3 has 2 zinc finger domains, which play an important role in the increase in target gene transcription activity. A 50-year-old woman and her 27-year-old daughter were followed up because of hypoparathyroidism. They had bilateral sensorineural deafness. Abdominal computed tomography scanning revealed renal dysplasia in the mother, but no renal anomaly in the daughter. Direct sequencing of GATA3 gene revealed a novel heterozygous missense mutation at codon 299 (p.R299Q) in exon 4. This mutation is located at the junction between the 2 zinc fingers. The structure prediction showed that it caused a conformation change in this junction area, affecting the spatial position of the zinc fingers. Additionally, a more marked conformation change was observed in the N-terminal zinc finger region compared to that in the C-terminal region. Functional analysis of this mutant protein using an in vitro luciferase reporter assay system confirmed that the mutation abolished the enhancing effects of wild-type GATA3 on the promoter activity of the consensus GATA responsive element and that of human PTH gene. We identified a novel R299Q mutation in GATA3 in a Japanese family with HDR syndrome. We confirmed that R299Q is a loss-of-function mutation, due to the extensive conformational change in the zinc fingers of GATA3.


    • 1 January 2014
      • Vol. 35  (5) , 342-6

    An unusual case of hypopituitarism and transient thyrotoxicosis following asymptomatic pituitary apoplexy.

    by Masanori Yoshida, Miho Murakami, Harumi Ueda, Misaki Miyata, Norio Takahashi, Yutaka Oiso

    Although pituitary function is often impaired in pituitary apoplexy, the development of thyrotoxicosis is rare. We describe an unusual case of hypopituitarism due to pituitary apoplexy coexisting with transient hyperthyroidism. A 74-year-old woman presented with severe fatigue, palpitation, appetite loss, hypotension, and hyponatremia. Endocrine studies showed hyperthyroidism and anterior pituitary hormone deficiencies. A magnetic resonance imaging suggested recent-onset pituitary apoplexy in a pituitary tumor, although the patient had no apoplectic symptoms such as headache and visual disturbance. Thyrotoxicosis and adrenal insufficiency worsened her general condition. Glucocorticoid supplementation improved her clinical symptoms and hyponatremia. Serum anti-thyrotropin receptor and thyroid-stimulating antibody titers were negative, and her thyroid function was spontaneously normalized without antithyroid medication, suggesting painless thyroiditis. Thereafter, her thyroid function decreased because of central hypothyroidism and 75 µg of levothyroxine was needed to maintain thyroid function at the euthyroid stage. The pituitary mass was surgically removed and an old hematoma was detected in the specimen. Considering that painless thyroiditis develops as a result of an autoimmune process, an immune rebound mechanism due to adrenal insufficiency probably caused painless thyroiditis. Although the most common type of thyroid disorder in pituitary apoplexy is central hypothyroidism, thyrotoxicosis caused by painless thyroiditis should be considered even if the patient has pituitary deficiencies. Because thyrotoxicosis with adrenal insufficiency poses a high risk for a life-threatening adrenal crisis, prompt diagnosis and treatment are critical.


  • Pathway analysis of single-microglia gene-expression profiles reveals the new molecular targets of minocycline treatment

    by Haruyuki Suzuki, Yoshihisa Sugimura, Shintaro Iwama, Hiromi Suzuki, Hiroshi Takagi, Atsushi Kiyota, Kazuki Fukuoka, Makoto Sawada, Yutaka Oiso

  • Proteomic analysis for identifying the pathogenic autoantigen of isolated adrenocorticotropin (ACTH) deficiency and lymphocytic adenohypophysitis

    by Atsushi Kiyota, Yoshihisa Sugimura, Shintaro Iwama, Haruyuki Suzuki, Hiroshi Takagi, Kazuki Fukuoka, Tomoki Nishioka, Atsushi Enomoto, Yutaka Oiso

  • Open Access

    Role of Endogenous Nociceptin in the Regulation of Arginine Vasopressin Release in Conscious Rats

    by Satoshi Kakiya, Takashi Murase, Hiroshi Arima, Hisashi Yokoi, Yasumasa Iwasaki, Yoshitaka Miura, Yutaka Oiso

    The effects of central administration of the opioid-like peptide nociceptin (also known as orphanin FQ) were investigated on the secretion of arginine vasopressin (AVP) in response to dehydration and hyperosmolar or hypovolemic stimulation in conscious rats. Intracerebroventricular (icv) administration of nociceptin suppressed plasma AVP concentration in a dose-dependent manner (0.1–10 μg/rat) in dehydrated rats, and the maximum effect was obtained 10 min after the administration (dehydration with 10 μg/rat nociceptin, 3.11± 0.27 pg/ml vs. control, 10.32 ± 0.96 pg/ml). The plasma AVP increase in response to either hyperosmolality [ip injection of hypertonic saline (HS) (600 mosml/kg)] or hypovolemia[ ip injection of polyethylene glycol (PEG)] was also significantly blunted when nociceptin was injected icv (HS with 10 μg/rat nociceptin, 1.16 ± 0.09 pg/ml vs. control, 1.82 ± 0.30 pg/ml; PEG with 10 μg/rat nociceptin, 0.91 ± 0.16 pg/ml vs. control, 2.41 ± 0.26 pg/ml). Pretreatment with a selective opioid κ-receptor antagonist, nor-binaltorphimine (1 μg/rat, icv) or naloxone (2.5 mg/rat, sc injection) did not reverse the inhibitory effects of nociceptin on AVP release. Moreover, when plasma AVP was suppressed by acute water loading, immunoneutralization of endogenous nociceptin by antinociceptin-antiserum icv significantly reversed the suppression (0.57 ± 0.12 pg/ml vs. control, 0.25 ± 0.04 pg/ml). These results suggest that central nociceptin is physiologically involved in the control of AVP release through an inhibitory action.


  • Open Access

    Antidiabetic Sulfonylurea Enhances Secretagogue-Induced Adrenocorticotropin Secretion and Proopiomelanocortin Gene Expression in Vitro

    by Minako Morishita, Yasumasa Iwasaki, Etsuko Yamamori, Atsushi Nomura, Noriko Mutsuga, Masanori Yoshida, Masato Asai, Yutaka Oiso, Hidehiko Saito

    The presence of high-affinity binding sites for antidiabetic sulfonylureas (SUs) and the expression of SU receptor (SUR) messenger RNA in the adenohypophyseal cells have recently been reported. In this study, we examined the effects of SU on POMC gene expression and ACTH secretion using the AtT20PL cell line, a subclone of AtT20 in which the rat POMC 5′-promoter-luciferase fusion gene was stably incorporated. A representative SU glibenclamide inhibited the basal POMC 5′-promoter activity. In contrast, glibenclamide enhanced forskolin- or CRH-induced POMC expression in a dose-dependent manner. Interestingly, the latter effect was not observed under treatment with 3-isobutyl-1-methylxanthine, a nonselective phosphodiesterase inhibitor. Furthermore, diazoxide, an opener of the ATP-sensitive K+ channel, only antagonized the suppressive effect of glibenclamide. Lastly, RT-PCR analysis showed that mouse SUR (but not SUR2) messenger RNA was expressed in this cell line. These results suggest that, in AtT20PL cells, SU has dual effects, i.e. a suppressive effect on basal POMC expression through diazoxide-sensitive (ATP-sensitive) K+-channel-mediated mechanism, and an enhancing effect on cAMP/protein kinase A-stimulated POMC expression through a different mechanism (probably mediated by phosphodiesterase). To our knowledge, this is the first report showing the effect of SU on the expression of the anterior pituitary hormone gene.


  • Open Access

    Cytokine Regulation of the Rat Proopiomelanocortin Gene Expression in AtT-20 Cells

    by Masahito Katahira, Yasumasa Iwasaki, Yoshiaki Aoki, Yutaka Oiso, Hidehiko Saito

    Although cytokines are known to be involved in the regulation of ACTH secretion, their effects, along with the molecular mechanisms, on POMC gene expression are not thoroughly characterized. In this study we examined the effects of representative cytokines on transcription of the POMC gene in corticotrophs in vitro using AtT20PL, a clone of the AtT20 cell line stably transfected with approximately 0.7 kilobase of the rat POMC 5′-promoter-luciferase fusion gene. In each experiment, cells were incubated with the cytokine tested, and the changes in POMC 5′-promoter activity were determined by a luciferase assay. The results showed that interleukin-1β (IL-1β) stimulated promoter activity in a biphasic manner [weak short term effects (2–3 h) followed by potent long term effects (>12–16 h)]. Tumor necrosis factor-α had similar effects, but much less potency. IL-6 showed a profound stimulatory, but only a long term (>20 h), effect. IL-2 did not influence POMC expression. In contrast, interferon-α (IFNα) and IFN-γ showed acute stimulatory effects (∼4 h) followed by marked inhibitory effects (>8 h). Although the acute effects of IL-1β, IL-6, and tumor necrosis factor-α alone were minimal, they significantly potentiated the stimulatory effect of CRH on POMC expression. Finally, pretreatment of the cells with a broad spectrum tyrosine kinase inhibitor, genistein, abolished or significantly diminished the effects of all cytokines except IFNs. Our results suggest that 1) each cytokine tested has a distinct effect on POMC gene expression; 2) there are positive cross-talk effects between CRH and cytokines at the corticotroph level; and 3) tyrosine phosphorylation cascades are involved in the intracellular signaling mechanisms of some cytokines.


  • Open Access

    Regulation of Vasopressin Synthesis and Release by Area Postrema in Rats

    by Hiroshi Arima, Kunikazu Kondo, Takashi Murase, Hisashi Yokoi, Yasumasa Iwasaki, Hidehiko Saito, Yutaka Oiso

    There is evidence indicating that the area postrema (AP), the most caudal circumventricular organ located on the dorsal surface of the medulla, is involved in several physiological regulations. In this study, we investigated the role of AP in the regulation of arginine vasopressin (AVP) synthesis and release, using rats of which the AP was lesioned 6 weeks previously. The level of plasma AVP in the AP lesioned (APX) group was significantly lower than in the sham operated (Sham) group in the basal state. AVP release induced by either hyperosmolality or hypovolemia was significantly attenuated by APX. To clarify the role of AP in AVP synthesis in the hypothalamus, we examined the AVP gene expression using in situ hybridization. AVP messenger RNA levels in paraventricular (PVN) and supraoptic nuclei (SON) in the APX group were significantly lower than in the Sham group in the basal state. Moreover, the AVP messenger RNA levels in PVN and SON in the APX group were also significantly lower than in the Sham group after water deprivation for 3 days. These results suggest that AVP synthesis and release are tonically stimulated by AP in the basal state and that AVP synthesis and release in stimulated states are also regulated, at least partially, by AP.


  • Intracerebroventricular injection of adrenomedullin inhibits vasopressin release in conscious rats

    by Hisashi Yokoi, Hiroshi Arima, Takashi Murase, Kunikazu Kondo, Yasumasa Iwasaki, Yutaka Oiso